pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·31m ago·1 min read
save

Ipsen says €2 billion cash reserves give it firepower for more M&A

Jul 30, 2026·read at Endpoints ↗DealPositive

Ipsen's CFO Aymeric Le Chatelier said the company ended June with €2 billion in cash, which it describes as "firepower" for acquisitions.

The cash position gives the French biotech firm flexibility to pursue additional M&A opportunities, according to the executive.

The statement signals that Ipsen may look to expand its portfolio in the near term, though no specific targets were disclosed.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Ipsen has 'firepower' for more deals with €2B war chest”

read at Endpoints ↗
86 words · retrieved 29m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoGerresheimer divests two businesses worth €1.5B; Resilience, Lilly boost injectable pen capacityEndpoints
  • 1h agoAlnylam cuts Amvuttra sales guidance as demand shifts, hurting stockEndpoints
  • 3h agoRelation promises 'transformationally different success rates' in expanded AI pact with GSKEndpoints
  • 5h agoSanofi records €1B+ write-off, ends work on two immunology assetsEndpoints
  • 10h agoJ&J lines up $2.58B option to buy Sail, Flagship's in vivo CAR-T biotechEndpoints